The present invention refers to a novel liquid pharmaceutical formulation comprising human antibodies to coagulation factor fxia as an effective component. The present invention also refers to the freeze dried matter of a particular liquid formulation and its use in the treatment and prevention of thrombotic or thromboembolic disorders.本発明は、有効成分として凝固因子FXIaに対するヒト抗体を含む新規な液体医薬製剤に言及する。本発明はまた、特定の液体製剤の凍結乾燥物、ならびに血栓性または血栓塞栓性障害の治療および予防におけるその使用にも言及する。